Sterling Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Sterling Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71K	Sell	565 -636	-53%	-$2.79K	﹤0.01%	2902
2026 Q1	$5.41K	Sell	1,201 -331	-22%	-$1.45K	﹤0.01%	2688
2025 Q4	$7.37K	Buy	1,532 +617	+67%	+$2.77K	﹤0.01%	2756
2025 Q3	$4.15K	Buy	915 +368	+67%	+$1.35K	﹤0.01%	2811
2025 Q2	$1.69K	Buy	547 +223	+69%	+$740	﹤0.01%	2957
2025 Q1	$1.13K	Sell	324 -125	-28%	-$417	﹤0.01%	2776
2024 Q4	$1.47K	Buy	449 +288	+179%	+$1.06K	﹤0.01%	2861
2024 Q3	$620	Buy	+161	New	+$618	﹤0.01%	2772
2015 Q2	–	Sell	-14,263	Closed	-$249K	–	872
2015 Q1	$249K	Buy	+14,263	New	+$292K	﹤0.01%	814

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sterling Capital Management's ABUS Position: Q2 2026 in Review

Sterling Capital Management reduced its Arbutus Biopharma (ABUS) stake by 53% in Q2 2026, selling an estimated $2.79K and leaving 565 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #2902.

Sterling Capital Management first reported a position in ABUS in Q1 2015 and has held it in 9 quarters since. The position peaked at $249K in Q1 2015. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Sterling Capital Management held 565 shares of Arbutus Biopharma worth $2.71K as of Q2 2026.
Sterling Capital Management sold 636 Arbutus Biopharma shares in Q2 2026, an estimated $2.79K.
Arbutus Biopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2902 holding.
Sterling Capital Management first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 9 quarters since.
Sterling Capital Management's Arbutus Biopharma position peaked at $249K in Q1 2015.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.